BACKGROUND: Transarterial liver-directed therapies are currently not recommended as a standard treatment for colorectal liver metastases. Transarterial chemoembolization (TACE), however, is increasingly used for patients with liver-dominant colorectal metastases after failure of surgery or systemic chemotherapy. The limited available data potentially reveals TACE as a valuable option for pre- and post-operative downsizing, minimizing time-to-surgery, and prolongation of overall survival after surgery in patients with colorectal liver only metastases. PURPOSE: In this overview, the current status of TACE for the treatment of liver-dominant colorectal liver metastases is presented. Critical comments on its rationale, technical success, complications, toxicity, and side effects as well as oncologic outcomes are discussed. The role of TACE as a valuable adjunct to surgery is addressed regarding pre- and post-operative downsizing, conversion to resectability as well as improvement of the recurrence rate after potentially curative liver resection. Additionally, the concept of TACE for liver-dominant metastatic disease with a focus on new embolization technologies is outlined. CONCLUSIONS: There is encouraging data with regard to technical success, safety, and oncologic efficacy of TACE for colorectal liver metastases. The majority of studies are non-randomized single-center series mostly after failure of systemic therapies in the 2nd line and beyond. Emerging techniques including embolization with calibrated microspheres, with or without additional cytotoxic drugs, degradable starch microspheres, and technical innovations, e.g., cone-beam computed tomography (CT) allow a new highly standardized TACE procedure. The real efficacy of TACE for colorectal liver metastases in a neoadjuvant, adjuvant, and palliative setting has now to be evaluated in prospective randomized controlled trials.
BACKGROUND: Transarterial liver-directed therapies are currently not recommended as a standard treatment for colorectal liver metastases. Transarterial chemoembolization (TACE), however, is increasingly used for patients with liver-dominant colorectal metastases after failure of surgery or systemic chemotherapy. The limited available data potentially reveals TACE as a valuable option for pre- and post-operative downsizing, minimizing time-to-surgery, and prolongation of overall survival after surgery in patients with colorectal liver only metastases. PURPOSE: In this overview, the current status of TACE for the treatment of liver-dominant colorectal liver metastases is presented. Critical comments on its rationale, technical success, complications, toxicity, and side effects as well as oncologic outcomes are discussed. The role of TACE as a valuable adjunct to surgery is addressed regarding pre- and post-operative downsizing, conversion to resectability as well as improvement of the recurrence rate after potentially curative liver resection. Additionally, the concept of TACE for liver-dominant metastatic disease with a focus on new embolization technologies is outlined. CONCLUSIONS: There is encouraging data with regard to technical success, safety, and oncologic efficacy of TACE for colorectal liver metastases. The majority of studies are non-randomized single-center series mostly after failure of systemic therapies in the 2nd line and beyond. Emerging techniques including embolization with calibrated microspheres, with or without additional cytotoxic drugs, degradable starch microspheres, and technical innovations, e.g., cone-beam computed tomography (CT) allow a new highly standardized TACE procedure. The real efficacy of TACE for colorectal liver metastases in a neoadjuvant, adjuvant, and palliative setting has now to be evaluated in prospective randomized controlled trials.
Authors: G Fiorentini; D B Poddie; M Cantore; S Rossi; S Tumolo; P Dentico; P Bernardeschi; S Guadagni; G Rossi; V M Valori; M De Simone Journal: J Chemother Date: 2004-11 Impact factor: 1.714
Authors: Huda S Salman; Jacov Cynamon; Marci Jagust; Curtis Bakal; Alla Rozenblit; Ron Kaleya; Abdissa Negassa; Scott Wadler Journal: Clin Colorectal Cancer Date: 2002-11 Impact factor: 4.481
Authors: Tatjana Gruber-Rouh; Nagy N N Naguib; Katrin Eichler; Hanns Ackermann; Stephan Zangos; Jörg Trojan; Martin Beeres; Marc Harth; Boris Schulz; Nour-Eldin Nour-Eldin A; Thomas J Vogl Journal: Int J Cancer Date: 2013-09-03 Impact factor: 7.396
Authors: Sarah A E Young; Joy Muthami; Mica Pitcher; Petar Antovski; Patricia Wamea; Robert Denis Murphy; Reihaneh Haghniaz; Andrew Schmidt; Samuel Clark; Ali Khademhosseini; Amir Sheikhi Journal: Mater Today Chem Date: 2021-12-30
Authors: Gergely Huszty; Attila Doros; Katalin Farkas; László Kóbori; Péter Reismann; Judit Tőke; Miklós Tóth; Peter Igaz Journal: Front Endocrinol (Lausanne) Date: 2021-04-30 Impact factor: 5.555
Authors: Carrie Howard; Thomas W Clements; Janet P Edwards; Anthony R MacLean; W Donald Buie; Elijah Dixon; Sean C Grondin; Anthony Gomes; Michael McColl; Sean P Cleary; Shiva Jayaraman; Renelle Daigle; Chad G Ball Journal: Hepatobiliary Surg Nutr Date: 2018-08 Impact factor: 7.293